Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
The price of Cytokinetics Inc (NASDAQ: CYTK) closed at $37.83 in the last session, down -0.94% from day before closing price of $38.19. In other words, the price has decreased by -$0.94 from its previous closing price. On the day, 2.18 million shares were traded. CYTK stock price reached its highest trading level at $39.145 during the session, while it also had its lowest trading level at $37.6.
Ratios:
We take a closer look at CYTK’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 6.76 and its Current Ratio is at 6.76.
On February 07, 2025, Citigroup started tracking the stock assigning a Buy rating and target price of $86.Citigroup initiated its Buy rating on February 07, 2025, with a $86 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Aug 19 ’25 when Malik Fady Ibraham sold 2,000 shares for $38.31 per share. The transaction valued at 76,620 led to the insider holds 140,610 shares of the business.
Blum Robert I sold 5,000 shares of CYTK for $192,100 on Aug 15 ’25. The President & CEO now owns 383,108 shares after completing the transaction at $38.42 per share. On Aug 05 ’25, another insider, Malik Fady Ibraham, who serves as the EVP Research & Development of the company, sold 2,000 shares for $36.34 each. As a result, the insider received 72,680 and left with 140,610 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CYTK now has a Market Capitalization of 4526624768 and an Enterprise Value of 4660253184. For the stock, the TTM Price-to-Sale (P/S) ratio is 52.79. Its current Enterprise Value per Revenue stands at 54.355 whereas that against EBITDA is -8.669.
Stock Price History:
The Beta on a monthly basis for CYTK is 0.63, which has changed by -0.34082592 over the last 52 weeks, in comparison to a change of 0.1590569 over the same period for the S&P500. Over the past 52 weeks, CYTK has reached a high of $59.39, while it has fallen to a 52-week low of $29.31. The 50-Day Moving Average of the stock is 4.99%, while the 200-Day Moving Average is calculated to be -8.79%.
Shares Statistics:
According to the various share statistics, CYTK traded on average about 1.42M shares per day over the past 3-months and 1559120 shares per day over the past 10 days. A total of 119.60M shares are outstanding, with a floating share count of 117.00M. Insiders hold about 2.22% of the company’s shares, while institutions hold 114.25% stake in the company. Shares short for CYTK as of 1755216000 were 15325098 with a Short Ratio of 10.76, compared to 1752537600 on 15929741. Therefore, it implies a Short% of Shares Outstanding of 15325098 and a Short% of Float of 16.700001.
